Segall Bryant & Hamill LLC Sells 28,247 Shares of Phibro Animal Health Corporation $PAHC

Segall Bryant & Hamill LLC lessened its stake in Phibro Animal Health Corporation (NASDAQ:PAHC) by 18.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 121,898 shares of the company’s stock after selling 28,247 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.30% of Phibro Animal Health worth $4,932,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. EverSource Wealth Advisors LLC raised its position in Phibro Animal Health by 7,671.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after buying an additional 2,685 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Phibro Animal Health by 768.2% in the second quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock valued at $118,000 after purchasing an additional 4,079 shares during the last quarter. Cornerstone Investment Partners LLC bought a new position in shares of Phibro Animal Health during the third quarter valued at about $209,000. Balboa Wealth Partners purchased a new position in Phibro Animal Health during the third quarter worth about $216,000. Finally, Jupiter Asset Management Ltd. purchased a new position in Phibro Animal Health during the third quarter worth about $228,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Insider Activity

In related news, CEO Jack Bendheim sold 7,040 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $53.73, for a total value of $378,259.20. Following the completion of the transaction, the chief executive officer directly owned 1,480 shares of the company’s stock, valued at approximately $79,520.40. This trade represents a 82.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 299,200 shares of company stock valued at $14,249,723 over the last 90 days. Insiders own 50.13% of the company’s stock.

Phibro Animal Health Stock Performance

NASDAQ:PAHC opened at $51.89 on Thursday. The company has a market capitalization of $2.10 billion, a P/E ratio of 23.06, a P/E/G ratio of 0.80 and a beta of 0.74. The business has a fifty day simple moving average of $44.68 and a two-hundred day simple moving average of $41.39. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $56.30.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The company had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be paid a $0.12 dividend. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 21.33%.

Wall Street Analysts Forecast Growth

Several research firms have commented on PAHC. JPMorgan Chase & Co. increased their price objective on shares of Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Finally, Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a research note on Friday, February 6th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $37.50.

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.